{"id":55532,"date":"2023-04-05T12:05:30","date_gmt":"2023-04-05T10:05:30","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/synthace-a-digital-experiment-platform-for-life-science-rd-records-strongest-year-yet\/"},"modified":"2023-04-05T12:05:30","modified_gmt":"2023-04-05T10:05:30","slug":"synthace-a-digital-experiment-platform-for-life-science-rd-records-strongest-year-yet","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/synthace-a-digital-experiment-platform-for-life-science-rd-records-strongest-year-yet\/","title":{"rendered":"Synthace, a Digital Experiment Platform for Life Science R&D, Records Strongest Year Yet"},"content":{"rendered":"
\n

LONDON & BOSTON–(BUSINESS WIRE)–#Automation<\/a>–Today, Synthace<\/a>,<\/b> a digital life science experiment platform, announces it has had its most successful year on record with major adoption and expansion with customers, industry recognition, product innovation, and a key hire at board level.<\/p>\n

<\/a><\/p>\n

\nMajor adoption and expansion among the top 100 pharma<\/b><\/p>\n

\nSynthace experienced 94% annual recurring revenue growth, 166% year-on-year growth in total contract value, and 170% net revenue retention (NRR) growth among customers. Trending above the average SaaS NRR number of 110-120%, this is especially impactful in the current economic climate where customer retention is crucial to survival for SaaS companies. Additionally, the company has received an \u2018Excellent\u2019 net promoter score of 55, and has experienced double account growth on average. This indicates the powerful scientific value that Synthace\u2019s digital experiment platform drives for its customers.<\/p>\n

\nSynthace is already deployed in 10 of the top 20 pharma companies around the world, and its customer accounts that fall within the top 100 pharma companies have grown by 2.3X.\u00a0 Additionally, the company gained 22 new customer expansions in the past year from 14 of the top pharma companies. A few current customers include AstraZeneca, Oxford Biomedical, Syngenta, and Ipsen.<\/p>\n

\nGuy Levy-Yurista Ph.D., Synthace CEO, said, \u201c2022 has proven the core value of our product to life science R&D teams. Our results reflect the strong adoption and expansion of the platform across teams within these companies, along with the adoption of new features released by our product team. Whether it is through its DOE for drug discovery, scale-down purification workflows, or bioprocessing innovations, the value of Synthace’s platform to our customers is demonstrated on a daily basis. At the end of this fiscal year, we can say that Synthace is positioned as a key partner for the world\u2019s best R&D teams.\u201d<\/p>\n

\nIndustry recognition: growth beyond the numbers<\/b><\/p>\n

\nAlongside strong topline growth indicators, Synthace has been <\/b>recognized by leading industry bodies and publications: <\/b><\/p>\n